01—Abstract
Summary
Summary of the 8-K filed November 7, 2024. Cited figures are marked; the original filing is the authoritative source.
BD (Becton, Dickinson and Company) reported fiscal Q4 and full-year 2024 results (quarter ended September 30, 2024) that showed solid top-line growth, sharp margin and cash flow improvement, and FY25 guidance that embeds a large acquisition contribution.
Q4 revenue rose 6.9% as reported to $5.44 billiona (6.2% organic), with BD Medical up 11.1% led by Medication Management Solutions and the newly acquired Advanced Patient Monitoring (Edwards Critical Care) business, which contributed only about one month of revenue. Q4 GAAP diluted EPS from continuing operations was $1.45, up 173.6%, but this comparison is flattered by a prior-year $563 million product remediation charge; adjusted EPS grew a more modest 11.4% to $3.81. Operating income rose 86% to $650 million, largely on the lapping of that prior-year charge.
For the full year, revenue grew 4.2% to $20.2 billionb (5.0% organic), adjusted diluted EPS rose 7.6% to $13.14, and free cash flow grew 47.4% to $3.1 billion. Balance sheet leverage increased meaningfully: long-term debt reached $17.9 billion, up from $14.7 billion, to fund the roughly $3.9 billion Critical Care acquisition. Management guided FY25 GAAP revenue growth of 8.9% to 9.4% (about $21.9 to $22.1 billion), with organic growth of only 4.0% to 4.5%, implying that acquisitions add roughly 475 basis points.
Adjusted EPS guidance of $14.25 to $14.60c implies about 8.5% to 11% growth. Investors should note that organic growth guidance includes an approximately 125 basis point headwind from China and bioscience/pharma market dynamics, and that the company disclosed a $175 million accrual for an SEC investigation related to Alaris pump reporting, with potential exposure that could exceed the accrued amount.
02—Key points
Key Highlights
- Q4 FY24 revenue of $5.44 billion grew 6.9% as reported and 6.2% organically; BD Medical grew 11.1% reported, led by Medication Management Solutions
- Q4 GAAP diluted EPS of $1.45 (up 173.6%) is inflated by lapping a $563 million prior-year product remediation charge; adjusted diluted EPS rose 11.4% to $3.81
- FY24 free cash flow grew 47.4% to $3.1 billion and cash from continuing operations rose 28.5% to $3.8 billion
- FY25 guidance: GAAP revenue growth of 8.9% to 9.4% but organic growth of only 4.0% to 4.5%, with acquisitions contributing about 475 bps
- FY25 adjusted diluted EPS guidance of $14.25 to $14.60 implies roughly 8.5% to 11% growth, with a ~125 bp organic revenue headwind from China and bioscience/pharma
- Long-term debt rose to $17.9 billion from $14.7 billion, reflecting financing of the Edwards Critical Care acquisition (about $3.9 billion net cash outlay)
- Disclosed a $125 million Q4 accrual (cumulative $175 million for FY24) for an SEC investigation into Alaris pump reporting, with potential exposure that could exceed the accrued amount
03—Questions
Frequently Asked Questions
How did BD perform in the fourth quarter of fiscal 2024?
Revenue rose 6.9% as reported to $5.44 billion, or 6.2% on an organic basis. Adjusted diluted EPS grew 11.4% to $3.81. GAAP diluted EPS of $1.45 is up sharply, but mainly because the prior year included a large product remediation charge.
What is driving the big jump in GAAP earnings?
Q4 FY23 included a $563 million charge to adjust estimated future product remediation costs, which depressed that period's results. Lapping this charge, along with strong BD Medical growth, drove operating income up 86% to $650 million. Underlying adjusted growth was much more modest.
Why is organic growth guidance for FY25 much lower than GAAP revenue growth?
The Edwards Critical Care (Advanced Patient Monitoring) acquisition adds roughly 475 basis points to FY25 reported growth. Organic growth of 4.0% to 4.5% excludes this contribution and absorbs about a 125 bp headwind from China and bioscience/pharma market dynamics.
What are the main legal and financial risks disclosed?
BD accrued $125 million in Q4 (and $175 million for FY24) for an SEC investigation into reporting on Alaris infusion pumps before 2021. The company says the final outcome is unknown and the liability could significantly exceed the accrual. Leverage also rose, with long-term debt up to $17.9 billion.
04—Continue